The Risk of Venous Thromboembolism Attributed to Established Prothrombotic Genotypes

Abstract

Background The proportion of venous thromboembolism (VTE) events that can be attributed to established prothrombotic genotypes has been scarcely investigated in the general population. We aimed to estimate the proportion of VTEs in the population that could be attributed to established prothrombotic genotypes using a population-based case-cohort.

Methods Cases with incident VTE (n = 1,493) and a randomly sampled subcohort (n = 13,069) were derived from the Tromsø Study (1994–2012) and the Nord-Trøndelag Health (HUNT) study (1995–2008). DNA samples were genotyped for 17 single-nucleotide polymorphisms (SNPs) associated with VTE. Hazard ratios with 95% confidence intervals (CIs) were estimated in Cox regression models. Population-attributable fractions (PAFs) with 95% bias-corrected CIs (based on 10,000 bootstrap samples) were estimated using a cumulative model where SNPs significantly associated with VTE were added one by one in ranked order of the individual PAFs.

Results Six SNPs were significantly associated with VTE (rs1799963 [Prothrombin], rs2066865 [FGG], rs6025 [FV Leiden], rs2289252 [F11], rs2036914 [F11], and rs8176719 [ABO]). The cumulative PAF for the six-SNP model was 45.3% (95% CI: 19.7–71.6) for total VTE and 61.7% (95% CI: 19.6–89.3) for unprovoked VTE. The PAF for prothrombotic genotypes was higher for deep vein thrombosis (DVT; 52.9%) than for PE (33.8%), and higher for those aged <70 years (66.1%) than for those aged ≥70 years (24.9%).

Conclusion Our findings suggest that 45 to 62% of all VTE events in the population can be attributed to known prothrombotic genotypes. The PAF of established prothrombotic genotypes was higher in DVT than in PE, and higher in the young than in the elderly.

Keywords

venous thromboembolism - single-nucleotide polymorphisms - risk factors

• References

• 1 Lijfering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis - current understanding from an epidemiological point of view. Br J Haematol 2010; 149 (06) 824-833
• 2 Crous-Bou M, Harrington LB, Kabrhel C. Environmental and genetic risk factors associated with venous thromboembolism. Semin Thromb Hemost 2016; 42 (08) 808-820
• 3 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-530
• 4 Germain M, Chasman DI, de Haan H. et al; Cardiogenics Consortium. Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism. Am J Hum Genet 2015; 96 (04) 532-542
• 5 Trégouët DA, Morange PE. What is currently known about the genetics of venous thromboembolism at the dawn of next generation sequencing technologies. Br J Haematol 2018; 180 (03) 335-345
• 6 Morange PE, Suchon P, Trégouët DA. Genetics of venous thrombosis: update in 2015. Thromb Haemost 2015; 114 (05) 910-919
• 7 Klarin D, Emdin CA, Natarajan P, Conrad MF, Kathiresan S. INVENT Consortium. Genetic analysis of venous thromboembolism in UK Biobank identifies the ZFPM2 locus and implicates obesity as a causal risk factor. Circ Cardiovasc Genet 2017; 10 (02) e001643
• 8 Klarin D, Busenkell E, Judy R. et al; INVENT Consortium, Veterans Affairs' Million Veteran Program. Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Nat Genet 2019; 51 (11) 1574-1579
• 9 Lindström S, Wang L, Smith EN. et al; Million Veteran Program, CHARGE Hemostasis Working Group. Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism. Blood 2019; 134 (19) 1645-1657
• 10 de Haan HG, Bezemer ID, Doggen CJ. et al. Multiple SNP testing improves risk prediction of first venous thrombosis. Blood 2012; 120 (03) 656-663
• 11 Witte JS, Visscher PM, Wray NR. The contribution of genetic variants to disease depends on the ruler. Nat Rev Genet 2014; 15 (11) 765-776
• 12 Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. Am J Public Health 1998; 88 (01) 15-19
• 13 Heit JA, Cunningham JM, Petterson TM, Armasu SM, Rider DN, DE Andrade M. Genetic variation within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways as risk factors for venous thromboembolism. J Thromb Haemost 2011; 9 (06) 1133-1142
• 14 Arshad N, Isaksen T, Hansen JB, Brækkan SK. Time trends in incidence rates of venous thromboembolism in a large cohort recruited from the general population. Eur J Epidemiol 2017; 32 (04) 299-305
• 15 Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost 2010; 8 (10) 2105-2112
• 16 van Langevelde K, Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Cannegieter SC. Broadening the factor V Leiden paradox: pulmonary embolism and deep-vein thrombosis as 2 sides of the spectrum. Blood 2012; 120 (05) 933-946
• 17 Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T, Njølstad I. Cohort profile: the Tromso study. Int J Epidemiol 2012; 41 (04) 961-967
• 18 Holmen J, Midthjell K, Krüger Ø. et al. The Nord-Trøndelag Health Study 1995–1997 (HUNT 2): objectives, contents, methods and participation. Nor Epidemiol 2003; 13: 19-32
• 19 Braekkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Størmer J, Hansen JB. Family history of myocardial infarction is an independent risk factor for venous thromboembolism: the Tromsø study. J Thromb Haemost 2008; 6 (11) 1851-1857
• 20 Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5 (04) 692-699
• 21 Horvei LD, Braekkan SK, Smith EN. et al. Joint effects of prothrombotic genotypes and body height on the risk of venous thromboembolism: the Tromsø study. J Thromb Haemost 2018; 16 (01) 83-89
• 22 Li Y, Bezemer ID, Rowland CM. et al. Genetic variants associated with deep vein thrombosis: the F11 locus. J Thromb Haemost 2009; 7 (11) 1802-1808
• 23 Johnson CY, Tuite A, Morange PE, Tregouet DA, Gagnon F. The factor XII -4C>T variant and risk of common thrombotic disorders: a HuGE review and meta-analysis of evidence from observational studies. Am J Epidemiol 2011; 173 (02) 136-144
• 24 Sode BF, Allin KH, Dahl M, Gyntelberg F, Nordestgaard BG. Risk of venous thromboembolism and myocardial infarction associated with factor V Leiden and prothrombin mutations and blood type. CMAJ 2013; 185 (05) E229-E237
• 25 Zapata-Diomedi B, Barendregt JJ, Veerman JL. Population attributable fraction: names, types and issues with incorrect interpretation of relative risks. Br J Sports Med 2018; 52 (04) 212-213
• 26 Bhopal RJ. Concepts of Epidemiology. Integrating the Ideas, Theories, Principles, and Methods of Epidemiology. 3rd ed. Oxford: Oxford University Press; 2016
• 27 Roach REJ, Cannegieter SC, Lijfering WM. Differential risks in men and women for first and recurrent venous thrombosis: the role of genes and environment. J Thromb Haemost 2014; 12 (10) 1593-1600
• 28 Zöller B, Melander O, Svensson PJ, Engström G. Factor V Leiden paradox in a middle-aged Swedish population: a prospective study. Vasc Med 2018; 23 (01) 52-59
• 29 Folsom AR, Cushman M, Tsai MY, Heckbert SR, Aleksic N. Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and incidence of venous thromboembolism. Am J Hematol 2002; 71 (04) 285-290
• 30 Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999; 82 (02) 610-619
• 31 Weingarz L, Schwonberg J, Schindewolf M. et al. Prevalence of thrombophilia according to age at the first manifestation of venous thromboembolism: results from the MAISTHRO registry. Br J Haematol 2013; 163 (05) 655-665
• 32 Lindström S, Brody JA, Turman C. et al; INVENT Consortium. A large-scale exome array analysis of venous thromboembolism. Genet Epidemiol 2019; 43 (04) 449-457
• 33 Shaya SA, Westrick RJ, Gross PL. Thrombus stability explains the factor V Leiden paradox: a mouse model. Blood Adv 2019; 3 (21) 3375-3378
• 34 Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen CJ. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2009; 169 (06) 610-615
• 35 Zöller B, Li X, Sundquist J, Sundquist K. Age- and gender-specific familial risks for venous thromboembolism: a nationwide epidemiological study based on hospitalizations in Sweden. Circulation 2011; 124 (09) 1012-1020
• 36 Rockhill B, Weinberg CR, Newman B. Population attributable fraction estimation for established breast cancer risk factors: considering the issues of high prevalence and unmodifiability. Am J Epidemiol 1998; 147 (09) 826-833
• 37 Goumidi L, Thibord F, Wiggins KL. et al. Association between ABO haplotypes and the risk of venous thrombosis: impact on disease risk estimation. Blood 2021; 137 (17) 2394-2402